Design and development of thermoreversible ophthalmic in situ hydrogel of moxifloxacin HCL

Current Drug Delivery

Volumn 7, Issue 3, 2010, Pages 238-243

  Shastri, D H ^a   Prajapati, S T ^b   Patel, L D ^c  

^a K B INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH   (India)

^b Shri Sarvajanik Pharmacy College   (India)

^c C U SHAH UNIVERSITY   (India)

Author keywords

Ophthalmic in situ hydrogel; Poloxamer 188; Poloxamer 407; Xanthan gum and sodium alginate

Indexed keywords

ALGINIC ACID; MOXIFLOXACIN; POLOXAMER; XANTHAN; ANTIINFECTIVE AGENT; BACTERIAL POLYSACCHARIDE; DELAYED RELEASE FORMULATION; DRUG CARRIER; GLUCURONIC ACID; HEXURONIC ACID; HYDROGEL; QUINOLONE DERIVATIVE;

ARTICLE; CORNEA; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; GELATION; HYDROGEL; IN SITU HYDROGEL; IN VITRO STUDY; MUCOADHESION; PH; PRIORITY JOURNAL; TEMPERATURE; TEMPERATURE DEPENDENCE; ADHESION; ANIMAL; CHEMICAL MODEL; CHEMISTRY; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; INTRAOCULAR DRUG ADMINISTRATION; KINETICS; MEDICINAL CHEMISTRY; METABOLISM; SHEEP; SOLUBILITY;

ADHESIVENESS; ADMINISTRATION, OPHTHALMIC; ALGINATES; ANIMALS; ANTI-BACTERIAL AGENTS; CHEMISTRY, PHARMACEUTICAL; CORNEA; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; FLUOROQUINOLONES; GLUCURONIC ACID; HEXURONIC ACIDS; HYDROGELS; HYDROGEN-ION CONCENTRATION; KINETICS; MODELS, CHEMICAL; POLOXAMER; POLYSACCHARIDES, BACTERIAL; SHEEP; SOLUBILITY; TEMPERATURE;

EID: 77954664325     PISSN: 15672018     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720110791560928     Document Type: Article

References (26)

1. Ashim K. M.; Ophthalmic Drug Delivery System. Marcel Dekker, New York, USA, 1993, Vol. 58, pp. 105-110.
2. Indu P.; Kaur A.G.; Anil K. S.; Deepika A. Vesicular systems in ocular drug delivery an overview. Int. J. Pharm., 2004, 269, 1-14.
3. Saettone M. F. Progress and problems in ophthalmic drug delivery. Business briefing. Pharmatechnology, 2002, 167-170.
4. nd ed., Marcel Dekker Inc., New York, 1992, p. 1.
5. Bourlais C. L.; Acar L.; Zia H.; Sado P. A.; Needham T.; Leverge R. Ophthalmic drug delivery systems-recent advances. Prog. Retin. Eye. Res., 1998, 77(1), 33-58.
6. Paulsson M.; Hagerstrom H.; Edsman K. Rheological studies of the gelation of deacetylated gellan gum (Gelrite) in physiological conditions. Eur. J. Pharm. Sci., 1999, 9, 99-105.
7. Chien Y.W. Ocular Drug Delivery and Delivery Systems; Chapter 6. Novel Drug Delivery Systems; Marcel Dekker: New York, USA, 1996, pp. 269-270.
8. Biedenbach D. J.; Jones R. N. The comparative antimicrobial activity of Levofloxacin tested against 350 clinical isolates of Streptococci. Diagn. Microbiol. Infect. Dis., 1996, 25, 47-51.
9. Dalhoff A.; Petersen U.; Endermann R. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone. Chemotherapy. 1996, 42, 410-425.
10. Davis R.; Bryson H. M. Levofloxacin: a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs, 1994, 47, 677-700.
11. Gariepy E. R.; Lerous J. C.; In situ forming hydrogels-review of temperature sensitive systems. Eur. J. Pharm. Biopharm., 2004, 58, 409-426.
12. Cabana A.; Kadi A. I.; Juhasz J.; Study of the gelation process of polyethylene oxide-polypropylene oxide copolymer (poloxamer 407) aqueous solutions. J. Colloid. Interface Sci., 1997, 19, 307-312.
13. Karmarkar A. B.; Gonjari I. D.; Hosmani A. H.; Poloxamers and their applications. Online Int. J. Pharm., 2008.
14. Schmolka I. R.; Artificial skin I. Preparation and properties of Pluronic F 127 gels for treatment of burns. J. Biomed. Mater. Res., 1972, 6, 571-582.
15. Abhaham C. Poloxamer gel systems with gelling temperatures higher than room temperature. Patent No. 1072413, 1994.
16. Schmolka I. R. Clear analgesic gels with reduced tackiness. US Patent No. 4511563, 1985.
17. Gilbert J. C.; Richardson J. L.; Davies M. C.; Palin K. J. The effect of solutes and polymers on the gelation properties of Pluronic F 127 solutions for controlled drug delivery. J. Control. Release, 1987, 5, 113-118.
18. Miller S. C.; Drabic B. R.; Rheological properties of poloxamer vehicles. Int. J. Pharm., 1984, 18, 269-276.
19. Edsman K.; Carlfors J.; Peterson R.; Rheological evaluation of Poloxamer as in situ gel for ophthalmic use. Eur. J. Pharm. Sci., 1998, 6, 105-112.
20. Schmolka I. R.; A review of block polymer surfactants. J Am. Oil Chem. Soc., 1977, 54, 110-116.
21. Khan S.; Singhara D. S.; and Yeole P. G. Temperature induced in situ gel of lidocaine hydrochloride for periodontal anesthesia. Indian Drugs, 2005, 42(8), 519-524.
22. Gilbert J. C.; Richardson J. L.; Davies M. C.; Palin K. J.; Hadgraft J. The effect of solutes and polymers on the gelation properties of Pluronic F127 solutions for controlled drug delivery. J. Control Release, 1987, 5, 113-118.
23. ® gellan gum based ocular delivery system of indomethacin. Acta Pharm., 2003, 53, 251-261.
24. Puglia C.; Bonina F.; Trapani G.; Franco M.; Ricci M. Evaluation of in vitro percutaneous absorption of lorazepam and clonazepam from hydro-alcoholic gel formulations. Int. J. Pharm., 2001, 228, 79-87.
25. Choi H. G.; Jung J. H.; Ryu J. M.; Yoon S. J.; Oh Y. K.; Kim C. K. Development of in situ-gelling and mucoadhesive acetaminophen liquid suppository. Int. J. Pharm., 1998, 165, 33-44.
26. Cohn S.; Lobel E.; Trevgoda A.; Peled Y.; A novel in situ-forming ophthalmic drug delivery system from alginates undergoing gelation in the eye. J. Control Release, 1997, 44, 201-208.